

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SDR06A(10-01)  
Approved for use through 10/31/2002. OMB 831-0031  
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	10/788,906
Filing Date	February 27, 2004
First Named Inventor	Girouard, Steven
Group Art Unit	3766
Examiner Name	Reidel, Jessica

Sheet 1 of 5

Attorney Docket No: 279.696US1

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
Ⓢ	US-2002/0110910A1	08/15/2002	Gwathmey, Judith K., et al.	11/21/2001
	US-2002/0147329A1	10/10/2002	Luyten, Frank P., et al.	12/19/2001
	US-2003/0060854A1	03/27/2003	Zhu, Qingsheng	09/25/2001
	US-2003/0105493A1	06/05/2003	Salo, Rodney W.	12/05/2001
	US-2003/0144702A1	07/31/2003	Yu, Yinghong, et al.	12/09/2002
	US-2003/0144703A1	07/31/2003	Yu, Yinghong, et al.	12/09/2002
	US-2003/0148351A1	08/07/2003	Henry, Stephen P., et al.	12/13/2002
	US-2003/0216476A1	11/20/2003	Kleemann, Heinz-Werner	05/05/2003
	US-2004/0158290A1	08/12/2004	Girouard, Steven D., et al.	11/25/2003
	US-2005/0137631A1	06/23/2005	Yu, Yinghong, et al.	12/22/2003
	US-2005/0192637A1	09/01/2005	Girouard, Steven D., et al.	02/27/2004
	US-2005/0288721A1	12/29/2005	Girouard, S. D., et al.	06/07/2004
	US-5,025,786	06/25/1991	Siegel, Sharon B.	07/21/1988
	US-5,103,821	04/14/1992	King, W. L.	11/30/1990
	US-5,130,141	07/14/1992	Law, Peter K., et al.	05/30/1991
	US-5,486,359	01/23/1996	Caplan, Arnold I., et al.	02/08/1994
	US-5,543,318	08/06/1996	Smith, David A., et al.	09/21/1995
	US-5,580,779	12/03/1996	Smith, David A., et al.	04/04/1995
	US-5,610,172	03/11/1997	Weidmann, Klaus, et al.	03/24/1995
	US-5,855,610	01/05/1999	Vacanti, Joseph P., et al.	05/19/1995
	US-5,865,787	02/02/1999	Shapland, James E., et al.	09/13/1996
	US-5,873,904	02/23/1999	Ragheb, Anthony O., et al.	02/24/1997
	US-6,005,009	12/21/1999	Murad, Saood, et al.	03/20/1997
	US-6,083,930	07/04/2000	Roufa, Dikla, et al.	06/06/1995
	US-6,090,622	07/18/2000	Gearhart, John D., et al.	03/31/1997
	US-6,096,070	08/01/2000	Ragheb, Anthony O., et al.	05/16/1996
	US-6,199,554	09/19/2000	Plankenhorst, Wolfgang	07/11/1997
	US-6,245,566	06/12/2001	Gearhart, John D., et al.	03/31/1998
	US-6,436,672	08/20/2002	Tomlinson, James E.	12/29/1999
	US-6,468,985	10/22/2002	Huang, Shi	03/17/2000
	US-6,596,745	07/22/2003	Gall, Martin	05/30/2002
	US-6,610,716	08/26/2003	Wagle, Dilip R., et al.	07/13/2001
	US-6,660,737	12/09/2003	Almstead, Ji-In K., et al.	04/29/2002
	US-6,666,826	12/23/2003	Salo, R., et al.	01/04/2002
✓	US-7,039,462	05/02/2006	Pastore, J. M., et al.	06/14/2002

EXAMINER

Jessica J. Reidel

DATE CONSIDERED

09/20/06


Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB-009 (10-01)  
Approved for use through 10/31/2002. OMB 0314-0031  
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	10/788,906
Filing Date	February 27, 2004
First Named Inventor	Girouard, Steven
Group Art Unit	3766
Examiner Name	Reidel, Jessica

Sheet 2 of 5

Attorney Docket No: 279.696US1

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
ⓧ	WO-04016200	02/26/2004	Pavcnik, Dusan, et al.	
↓	WO-2005120635A1	12/22/2005	Girouard, S. D., et al.	
	WO-2006019856A1	02/23/2006	Girouard, S., et al.	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ⓧ		"COOK SIS Technology: Scientific Information: Clinical References", <a href="http://www.cooksis.com/sci/ref1.html">http://www.cooksis.com/sci/ref1.html</a> , (2004), 4 pgs.	
		"COOK SIS Technology: Scientific Information: Safety", <a href="http://www.cooksis.com/sci/tech3.html">http://www.cooksis.com/sci/tech3.html</a> , (2004), 2 pgs.	
		"COOK SIS Technology: Scientification Information: Tissue Repair: Challenges & Complications", <a href="http://www.cooksis.com/sci/tech.html">http://www.cooksis.com/sci/tech.html</a> , (2004), 2 pgs.	
		AKIYAMA-UCHIDA, Y., et al., "Norepinephrine enhances fibrosis mediated by TGF-beta in cardiac fibroblasts", <i>Hypertension</i> , 40(2), (Aug., 2002), 148-54	
		AUKRUST, PAL, et al., "Immunomodulating Therapy: New Treatment Modality in Congestive Heart Failure", <i>Congest Heart Fail.</i> , 9(2), (Mar.-Apr., 2003), 64-69	
		BADER, A., et al., "Tissue engineering of heart valves A? human endothelial cell seeding of detergent acellularized porcine valves", <i>Eur J Cardiothorac Surg</i> , 14(3), (Sept., 1998), 279-84	
		BELL, E., <i>Tissue Engineering: Current Perspectives</i> , Burkhauser Publishers, Cambridge, MA, (1993), 179-189	
		BIGATEL, D. A., et al., "The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms", <i>J Vasc Surg</i> , 29(1), (1999), 130-8	
		CAPECCHI, M. R., "High efficiency transformation by direct microinjection of DNA into cultured mammalian cells.", <i>Cell</i> , 22(2 Pt 2), (Nov., 1980), 479-88	
		CHU, G., "SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen.", <i>Gene</i> , 13(2), (Mar., 1981), 197-202	
		COLUCCI, WILSON S., "Molecular and Cellular Mechanisms of Myocardial Failure", <i>Am J Cardiol</i> 80(11A), (1997), 15L-25L	
		COURTMAN, D. W., et al., "Development of a pericardial acellular matrix biomaterial: Biochemical and mechanical effects of cell extraction", <i>J Biomed Mater Res.</i> , 28(6), (1994), 655-66	
		CSEKJESI, P., "Myogenin induces the myocyte-specific enhancer binding factor MEF-2 independently of other muscle-specific gene products", <i>Mol Cell Biol</i> , 11(10), (Oct., 1991), 4854-62	
↓		CURIEL, D. T., et al., "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery", <i>Proc Natl Acad Sci USA</i> , 88(19), (Oct. 1, 1991), 8850-4	

EXAMINER

DATE CONSIDERED

09/20/06


Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB08A (10-01)  
Approved for use through 10/31/2002. OMB 05-1-0001  
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	10/788,906
Filing Date	February 27, 2004
First Named Inventor	Girouard, Steven
Group Art Unit	3766
Examiner Name	Reidel, Jessica

Sheet 3 of 5

Attorney Docket No: 279.696US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
R		CURTIL, A., et al., "Freeze Drying of Cardiac Valves in Preparation for Cellular Repopulation", <u>Cryobiology</u> , 34(1), (Feb., 1997), 13-22	
		DHAWAN, J., "Tetracycline-regulated gene expression following direct gene transfer into mouse skeletal muscle", <u>Somat Cell Mol Genet.</u> , 21(4), (1995), 233-40	
		ECKARDT, LARS, et al., "Load-induced changes in repolarization: evidence from experimental and clinical data", <u>Basic Res Cardiol</u> , 96(4), (2001), 369-380	
		FELGNER, P. L., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", <u>Proceedings of the National Academy of Sciences</u> , 84, Biochemistry, (Nov. 1987), pp. 7413-7417	
		GRAHAM, F. L., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA", <u>Virology</u> , 52, (1973), 456-467	
		HAFIZI, S., et al., "Inhibition of human cardiac fibroblast mitogenesis by blockade of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.", <u>Cir Exp Pharma Physiol</u> , 26(7), (July, 1999), 511-3	
		HAMMOND, H. K., et al., "Regional myocardial downregulation of the inhibitory guanosine triphosphate-binding protein (Gi alpha 2) and beta-adrenergic receptors in a porcine model of chronic episodic myocardial ischemia", <u>J Clin Res</u> , 92(6), (1993), 2644-52	
		HIGASHI, T., et al., "Pharmacological characterization of endothelin-induced rat pulmonary arterial dilatation", <u>Br J Pharmacol</u> , 121(4), (1997), 782-6	
		JOHNSON, J. E., "Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice", <u>Mol Cell Biol.</u> , 9(8), (1989), 3393-9	
		JUGDUTT, BODH I., "Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways", <u>Current Drug Targets Cardiovascular &amp; Haematological Disorders</u> , 3, (2003), 1-30	
		KIBA, A., et al., "VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice.", <u>Biochem Biophys Res Commun.</u> , 301(2), (Feb. 7, 2003), 371-7	
		KLEIN, T. M., "High-Velocity Microprojectiles for Delivering Nucleic Acids into Living Cells", <u>Nature</u> , 327, (1987), 70-73	
		KODAMA, I., et al., "Cellular electropharmacology of amiodarone.", <u>Cardiovas Res</u> , 35(1), (1997), 13-29	
		LIJNEN, P. J., et al., "Induction of Cardiac Fibrosis by Transforming Growth Factor-B1", <u>Molecular Genetics and Metabolism</u> , 71, (2000), 418-435	
		MACKENNA, DEIDRE, et al., "Role of mechanical factors in modulating cardia fibroblast function and extracellular matrix synthesis", <u>Cardiovascular Research</u> , 46, (2000), 257-263	
Y		MADER, S., "A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells", <u>Proc Natl Acad Sci USA</u> , 90(12), (1993), 5603-7	

EXAMINER

*Jessica J. Reidel*

DATE CONSIDERED

09/20/06

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 4 of 5

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-91)  
Approved for use through 10/31/2002. OMB 051-0001  
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	10/788,906
Filing Date	February 27, 2004
First Named Inventor	Girouard, Steven
Group Art Unit	3766
Examiner Name	Reidel, Jessica

Attorney Docket No: 279.696US1

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		MANNINO, R. J., "Liposome mediated gene transfer.", <u>BioTechniques</u> , 6(7), (Jul.-Aug., 1988), 682-90	
		MUSCAT, G. E., "Multiple 5'-flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression", <u>Mol Cell Biol</u> , 7(11), (1987), 4089-99	
		PALERMO, J., "Transgenic remodeling of the contractile apparatus in the mammalian heart", <u>Circ Res</u> , 78(3), (1996), 504-9	
		POULEUR, H., et al., "Changes in plasma renin activity and haemodynamics during vasodilator therapy in conscious dogs with myocardial infarction or chronic volume overload.", <u>Eur J Clin Invest</u> , 13(4), (1983), 331-8.	
		POUZET, B., "Intramyocardial transplantation of autologous myoblasts: can tissue processing be optimized?", <u>Circulation</u> , 102(19 Suppl 3), (2000), III210-5	
		RINSCH, C., et al., "Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia", <u>Gene Therapy</u> , 8, (2001), 523-533	
		ROTH, D. A., et al., "Downregulation of cardiac guanosine 5'-triphosphate-binding proteins in right atrium and left ventricle in pacing-induced congestive heart failure", <u>J Clin Invest</u> , 91(3), (Mar., 1993), 939-49	
		SAM, FLORA, et al., "Role of Endothelin-1 in Myocardial Failure", <u>Proceedings of the Association of American Physicians</u> , 111(5), (1999), 417-422	
		SEMENZA, G. L., "Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gen", <u>Proc Natl Acad Sci USA</u> , 88(13), (1991), 5680-4	
		SEMENZA, G. L., "Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1", <u>J Biol Chem</u> , 269(38), (1994), 23757-63	
		SHIGEKAWA, K., "Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Introduction of Macromolecules into Cells", <u>BioTechniques</u> , 6, (1988), 742-751	
		SHOCKETT, P., "A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice", <u>Proc Natl Acad Sci USA</u> , 92(14), (1995), 6522-6	
		SUKENAGA, Y., et al., "Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities", <u>Jap J Pharmacol</u> , 90(3), (2002), 218-22	
		TAYLOR, D. A., et al., "Delivery of primary autologous skeletal myoblasts into rabbit heart by coronary infusion: a potential approach to myocardial repair", <u>Proc Assoc Am Phys</u> , 109(3), (May, 1997), 245-53	
✓		VILLARREAL, F. J., et al., "Human cardiac fibroblasts and receptors for angiotensin II and bradykinin: A potential role for bradykinin in the modulation of cardiac extracellular matrix", <u>Basic research in cardiology</u> , 93 Supp 3, (1998), s004 - s007	

EXAMINER

DATE CONSIDERED

09/20/06


Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 5 of 5

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/06A (10-01)  
Approved for use through 10/31/2002. OMB 93-0031  
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE**Complete if Known**

<b>Application Number</b>	10/788,906
<b>Filing Date</b>	February 27, 2004
<b>First Named Inventor</b>	Girouard, Steven
<b>Group Art Unit</b>	3766
<b>Examiner Name</b>	Reidel, Jessica

Attorney Docket No: 279.696US1

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
Ⓚ		WALTER, DIRK H., et al., "Endothelial progenitor cells: regulation and contribution to adult neovascularization", <u>Herz</u> , 27(7), (2002), 579-588	
		WANG, G. L., et al., "Molecular basis of hypoxia-induced erythropoietin expression", <u>Curr Opin Hematol.</u> , 3(2), (Mar., 1996), 156-62	
		WANG, L., et al., "Mutation of MEF2A in an inherited disorder with features of coronary artery disease", <u>Science</u> , 302(5650), (Nov. 28, 2003), 1578-81	
		WEINTRAUB, H., "The myoD gene family: nodal point during specification of the muscle cell lineage", <u>Science</u> , 251(4995), (Feb. 15, 1991), 761-6	
		YAGI, A., et al., "Anti-inflammatory constituents, aloesin and aloemannan in Aloe species and effects of tanshinon VI in Salvia miltiorrhiza on heart", <u>J Pharm Soc Japan</u> , 123(7), (July, 2003), 517-32	
↓		ZIMMERMANN, W. H., et al., "Tissue engineering of a differentiated cardiac muscle construct", <u>Circulation Res.</u> , 90(2), (2002), 223-30	

EXAMINER

Jessica L. Reidel

DATE CONSIDERED

09/20/06

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language translation is attached

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 Use as many sheets as necessary



Complete if Applicable

Application Number 10/788,906  
 Filing Date February 27, 2004  
 First Named Inventor Girouard, Steven  
 Group Art Unit 3762  
 Examiner Name Unknown



Sheet 10 of 15

Attorney Docket No: 279.696US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	Y
R		HODDE, JASON P., et al., "Retention of Endothelial Cell Adherence to Porcine-Derived Extracellular Matrix After Disinfection and Sterilization", <u>Tissue Engineering</u> , 8(2), (April 2002), 225-34	
		HONG, Y. S., et al., "Localized Immunosuppression in the Cardiac Allograft Induced by a New Liposome-Mediated IL-10 Gene Therapy", <u>J. Heart Lung Transplant</u> , 21, (2002), 1188-1200	
		HUQ, F., et al., "Session 5: Cellular and Subcellular Basis of Remodeling - Modulating Signalling Pathways in Hypertrophy and Heart Failure by Gene Transfer", <u>Journal of Cardiac Failure</u> , 8(6)(Suppl.), (2002), S389-S400	
		INGBER, DONALD E., "Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology", <u>Circulation Research</u> , 91(10), (November 15, 2002), 877-87	
		ISNER, JEFFREY M., "Myocardial Gene Therapy", <u>Nature</u> , Vol. 415, (January 10, 2002)	
		JACKSON, KATHYJO A., et al., "Regeneration of Ischemic Cardiac Muscle and Vascular Endothelium By Adult Stem Cells", <u>The Journal of Clinical Investigation</u> , Vol. 107, No. 11, (June 2001), 1395-1402 pgs.	
		JAIN, MOHIT, et al., "Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction", <u>Circulation</u> , 103(14), (April 10, 2001), 1920-1927	
		JAYAKUMAR, MD, J., et al., "Gene Therapy for Myocardial Prevention - Transfection of Donor Hearts With Heat Shock Protein 70 Gene Protects Cardiac Function Against Ischemia-Reperfusion Therapy", <u>Circulation</u> , 102 (Suppl. III), (2000), III-302-III-306	
		KEHAT, IZHAK, et al., "Human Embryonic stem Cells Can Differentiate into Myocytes with Structural and Functional Properties of Cardiomyocytes", <u>The Journal of Clinical Investigation</u> , Vol. 108, No. 3, (August 2001), pgs. 363-364	
		KOCH, W. J., et al., "Gene Transfer of B-Adrenergic Signalling Components for Heart Failure", <u>Journal of Cardiac Failure</u> , 8(6) (Suppl.), (2002), S526-S531	
		KOCHER, A A., et al., "Neovascularization of Ischemic Myocardium by Human Bone-Marrow-Derived Angioblasts Prevents Cardiomyocyte Apoptosis, Reduces Remodeling and Improves Cardiac Function", <u>Nature Medicine</u> , Vol. 7, No. 4, (April 2001), pgs. 430-436	
		KOMURO, ISSEI, et al., "Control of Cardiac Gene Expression by Mechanical Stress", <u>Annu Rev Physiol</u> , (1993), pgs 55-75	
		KOZARSKY, K. F., "Gene Therapy for Cardiovascular Disease", <u>Current Opinion in Pharmacology</u> , 1, (2001), 197-202	
		KRUM, HENRY, "New and Emerging Pharmacological Strategies in the Management of Chronic Heart Failure", <u>Current Opinion in Pharmacology</u> , 1(2), (April 2001), 126-33	

EXAMINER

*Julia J. Deibel*

DATE CONSIDERED

07/20/06

Substitute Disclosure Statement Form (PTO-1449)  
 \* EXAMINER: Initial & reference disclosed, whether or not checked in accordance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique accession designation number (optional) - Applicant to place a check mark here if English language Translation is attached